Real‐world effectiveness and safety of bimekizumab for hidradenitis suppurativa: An ambispective observational study

In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient‐reported outcomes at week 16, including a notable decrease in mea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Australasian journal of dermatology 2024-11, Vol.65 (7), p.e198-e202
Hauptverfasser:	Mansilla‐Polo, Miguel, Pons‐Benavent, Martí, Fernández‐Crehuet, Pablo, Vilarrasa, Eva, Albanell‐Fernández, Cristina, Morales‐Tedone, Enrico, Rausell‐Félix, Francisca, Alcalá‐García, Rebeca, Matellanes‐Palacios, María, Martín‐Ezquerra, Gemma, Alfageme, Fernando, Ciudad‐Blanco, Cristina, López‐Villaescusa, María Teresa, Garbayo‐Salmons, Patricia, Martorell, Antonio, Escutia‐Muñoz, Begoña, Navarro‐Blanco, Fernando, Martín‐Torregrosa, Daniel, Cuenca‐Barrales, Carlos, Molina‐Leyva, Alejandro, Botella‐Estrada, Rafael
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use bimekizumab biologic therapy Clinical trials Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use effectiveness Female hidradenitis suppurativa Hidradenitis Suppurativa - drug therapy Humans Male Middle Aged Patient Reported Outcome Measures safety Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this original research, we present the results in terms of effectiveness and safety of bimekizumab for hidradenitis suppurativa in real clinical practice. Results indicated significant improvement in all activity scores and patient‐reported outcomes at week 16, including a notable decrease in mean IHS4 from 27.1 to 15.6 (p
ISSN:	0004-8380 1440-0960 1440-0960
DOI:	10.1111/ajd.14339